Abstract
Malawi HIV treatment guidelines recommend same-day antiretroviral therapy (ART) initiation. Overall 97.9 % of Malawians living with HIV (PLHIV) are on ART, same-day ART initiation prevalence and factors that facilitate it have not been fully described. We assessed same-day ART initiation and described individual, health system and health facility infrastructural factors at health facilities supported by expert clients (EC). ECs are lay PLHIV who support other PLHIV. The study was conducted in urban and semi-urban primary health facilities, in Blantyre, Malawi. It was a cross-sectional, descriptive survey of PLHIV and health facility leaders. Eligibility criteria included age ≥ 18 years, new diagnosis of HIV, received counselling from ECs, and offered same day ART. The study was conducted from December 2018 to June 2021, and 321 study participants enrolled. Mean age (standard deviation) was 33 years (10) with 59% females. In total, 315 (98.1%) initiated same day ART. Four participants did not because of mental unpreparedness, one wanted to try herbal medicine and one was concerned about stigma. Participants reported health facility accessibility (99%,318/321), privacy (91%, 292/321) and quality of counselling by EC as excellent (40%,128/321). Same day ART was nearly universal. Participants’ satisfaction with health services delivery, the presence of EC, and infrastructural characteristics such as good privacy were cited as reasons favoring same day linkage to ART. The most cited reason for not starting same day ART was mental unpreparedness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Source of funding: Fogarty International Center, National Institutes of Health, Award Number D43TW0100600. VM received the award
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by College of Medicine Research Ethics Committee under the study approval number of P.06/18/2423
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This data was presented as a poster at International Conference on HIV Pathogenesis, and Prevention in Research Resource – Limited Settings (INTEREST), Kampala,12 May 22.
Source of funding: Fogarty International Center, National Institutes of Health, Award Number D43TW0100600.
Data Availability
All dataset will be made available in compliance with the PLOS Data Policy
